Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, and distribution/supply of diagnostic equipment for different diagnostic healthcare needs.

The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company's key manufacturing segments include indigenous manufacturing of reagents (Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Others [POC Devices & Rapid Tests]) and supplying/manufacturing of in-vitro diagnostics (IVD) and Pathology equipment & devices.

As of December 31, 2025, the total annual capacity was about 1.4 million kits (Haematology, Clinical Chemistry, Rapid/Elisa) and 1,200 Selectra Machines.

As on March 31, 2026, the company had 362 permanent employees.

Competitive Strengths :

Established manufacturing capabilities with focus on R&D, Reverse Engineering and quality control.

Diversified product portfolio with focus on IVD industry

Widespread distribution network with a presence across all four regions.

Long standing relationships with customers.

Experienced Promoter and Management team

Q-Line Biotech Limited IPO Allotment Status

IPO Timeline

Allotment